Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

NCT02835833 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT02835833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02835833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 1
Overall status
Completed
Start date
June 9, 2016
Completion date
June 14, 2018
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical carcinoma, colorectal adenocarcinoma, non-squamous non-small cell lung cancer, platinum-refractory ovarian carcinoma, renal cell carcinoma